CA3098514A1 - Mesenchymal stromal cell exosomes and uses thereof - Google Patents

Mesenchymal stromal cell exosomes and uses thereof Download PDF

Info

Publication number
CA3098514A1
CA3098514A1 CA3098514A CA3098514A CA3098514A1 CA 3098514 A1 CA3098514 A1 CA 3098514A1 CA 3098514 A CA3098514 A CA 3098514A CA 3098514 A CA3098514 A CA 3098514A CA 3098514 A1 CA3098514 A1 CA 3098514A1
Authority
CA
Canada
Prior art keywords
subject
msc
thymic
administered
exosome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3098514A
Other languages
English (en)
French (fr)
Inventor
Stella KOUREMBANAS
S. Alexander Mitsialis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of CA3098514A1 publication Critical patent/CA3098514A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3098514A 2018-04-30 2019-04-26 Mesenchymal stromal cell exosomes and uses thereof Pending CA3098514A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862664696P 2018-04-30 2018-04-30
US62/664,696 2018-04-30
PCT/US2019/029275 WO2019217091A1 (en) 2018-04-30 2019-04-26 Mesenchymal stromal cell exosomes and uses thereof

Publications (1)

Publication Number Publication Date
CA3098514A1 true CA3098514A1 (en) 2019-11-14

Family

ID=68466806

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3098514A Pending CA3098514A1 (en) 2018-04-30 2019-04-26 Mesenchymal stromal cell exosomes and uses thereof

Country Status (6)

Country Link
US (1) US12521418B2 (https=)
EP (1) EP3810271A4 (https=)
JP (2) JP7538044B2 (https=)
CN (1) CN112334190B (https=)
CA (1) CA3098514A1 (https=)
WO (1) WO2019217091A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2949083C (en) 2014-05-18 2023-10-10 Children's Medical Center Corporation Methods and compositions relating to exosomes
JP2021526556A (ja) 2018-05-30 2021-10-07 ダイレクト バイオロジクス エルエルシー 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞（ｍｓｃ）の調製物を含む助剤、ならびにその使用方法
BR112021015549A2 (pt) 2019-02-07 2021-10-26 Direct Biologics Llc Método para tratar osteoartrite com uma combinação de exossomos de células tronco mesenquimais, células tronco mesenquimais sinoviais e andaimes
CA3146433A1 (en) 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
CN111281889A (zh) * 2020-04-16 2020-06-16 博生众康(厦门)医药生物技术股份有限公司 人脐带间充质干细胞外泌体的用途
US12590310B2 (en) * 2020-04-22 2026-03-31 Direct Biologics, Llc Methods and compositions for treating inflammatory conditions associated with infectious disease
CN117363568B (zh) * 2023-12-04 2024-04-09 山东大学 一种脂肪间充质干细胞外泌体及其制备方法与应用
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
US8337815B2 (en) 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
WO2006110582A1 (en) 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
BRPI0617085A2 (pt) 2005-09-02 2016-11-08 Agency Science Tech & Res método para obter uma célula-tronco mesenquimal (msc), célula ou linhagem celular, método para derivar uma cultura celular a partir de uma célula-tronco embrionária, método para tratamento de uma doença, uso de uma célula-tronco mesenquimal, linhagem diferenciada, composição farmacêutica, método para condicionar um meio de cultura celular, meio condicionado e uso do mesmo, mpetodo para obterum polipeptídeo, método para obtar uma cultura celular, cultura celular, célula-tronco mesenquimal, linhagem de célula-tronco mesenquimal ou uma célula mesenquimal diferenciada
WO2007124594A1 (en) 2006-04-27 2007-11-08 Cell Therapy Technologies, Inc. Et Al. Stem cells for treating lung diseases
EP2617428A1 (en) 2006-08-15 2013-07-24 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
EP2076116A4 (en) 2006-10-11 2010-04-07 Gen Hospital Corp COMPOSITIONS, METHODS, AND DEVICES FOR TREATING HEPATIC DISEASES
EP1944361A1 (en) 2007-01-11 2008-07-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for expanding monocytes
CA2711218C (en) 2008-01-04 2019-08-06 Lydac Neuroscience Limited A method of producing a population of differentiated cells
CN102014934B (zh) 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
EP2456861A4 (en) 2009-07-23 2013-12-04 Agency Science Tech & Res PRENATAL MESENCHYMAL STEM CELLS
SG2014010698A (en) 2009-11-02 2014-05-29 Agency Science Tech & Res Methods of monitoring cellular states
KR101189655B1 (ko) 2010-06-30 2012-10-11 성균관대학교산학협력단 줄기세포 배양액을 포함하는 폐질환 치료용 조성물
CN101890050B (zh) 2010-07-14 2012-07-04 江苏大学 脐带间质干细胞来源膜性囊泡及其应用
CA2845280A1 (en) 2010-08-13 2012-02-16 Paul Shiels Therapeutic uses of microvesicles and related micrornas
WO2012115885A1 (en) 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
CA2829586C (en) 2011-03-11 2021-03-02 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
EP2721179A4 (en) 2011-06-16 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L BIOMARKER COMPOSITIONS AND METHOD THEREFOR
ITTO20111183A1 (it) 2011-12-21 2013-06-22 Univ Degli Studi Torino Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia
US9427450B2 (en) 2012-01-31 2016-08-30 Xon Cells, Inc. Therapeutic immune modulation by stem cell secreted exosomes
SG11201406336YA (en) 2012-04-03 2014-11-27 Reneuron Ltd Stem cell microparticles
KR101399056B1 (ko) 2012-04-16 2014-05-27 연세대학교 산학협력단 줄기세포-유래 미세소포체를 유효성분으로 포함하는 신경질환 예방 또는 치료용 약제학적 조성물
US20130273011A1 (en) 2012-04-17 2013-10-17 Medistem, Inc. Stem cells and stem cell generated nanoparticles for treatment of inflammatory conditions and acute radiation syndrome
EP2850178A4 (en) 2012-05-18 2015-10-28 Agency Science Tech & Res EXOSOMES OF MESHCHYMIC STROKE CELL OF UMBILICAL CORD
EP2687219A1 (en) 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
AU2013302526B2 (en) 2012-08-15 2018-03-22 The University Of Chicago Exosome-based therapeutics against neurodegenerative disorders
CN103767985A (zh) 2012-10-22 2014-05-07 吉林省霍普金斯药物研究院有限责任公司 人源血液或间充质干细胞分泌exosome的制备与应用
ES2927175T3 (es) 2013-02-12 2022-11-03 Reneuron Ltd Método de producción de micropartículas
AU2014251388B2 (en) 2013-04-12 2017-03-30 Evox Therapeutics Limited Therapeutic delivery vesicles
WO2015018915A1 (de) 2013-08-07 2015-02-12 Pi Ceramic Gmbh Keramische Technologien Und Bauelemente Piezokeramischer werkstoff mit reduziertem bleigehalt
SG11201601939VA (en) 2013-09-16 2016-04-28 Agency Science Tech & Res Method
US20180273906A1 (en) * 2014-04-17 2018-09-27 Muhammad Ashraf Microvesicle and stem cell compositions for therapeutic applications
CA2949083C (en) * 2014-05-18 2023-10-10 Children's Medical Center Corporation Methods and compositions relating to exosomes
EP3193890A4 (en) * 2014-09-15 2018-03-14 Agency For Science, Technology And Research Methods of treating graft versus host disease (gvhd) or epidermolysis bullosa (eb) with exosomes
US10166254B2 (en) 2014-09-19 2019-01-01 Wisconsin Alumni Research Foundation Use of mesenchymal stem cell-educated macrophages to treat and prevent graft versus host disease and radiation-induced injury
US20210205370A1 (en) * 2016-02-18 2021-07-08 Pluristem Ltd. Methods and compositions for treating cancers and neoplasms
CN105769916B (zh) 2016-04-29 2019-07-23 南京大学 间充质干细胞来源外泌体在制备治疗子痫前期药物或者制剂中的应用
KR20250037589A (ko) * 2016-06-17 2025-03-17 유나이티드 쎄러퓨틱스 코포레이션 향상된 효능을 가진 세포외 소포
KR101973284B1 (ko) 2017-01-16 2019-04-29 사회복지법인 삼성생명공익재단 신생아 ｈｉｅ 치료용 조성물
WO2018183825A1 (en) 2017-03-31 2018-10-04 Wisconsin Alumni Research Foundation Generation of therapeutic cells using extracellular components of target organs
CA3072562A1 (en) 2017-08-15 2019-02-21 Children's Medical Center Corporation Purified mesenchymal stem cell exosomes and uses thereof
US10876753B2 (en) 2018-02-12 2020-12-29 Watsco Ventures Llc Integrated sensor and service port for HVAC equipment or HVAC system
CA3099042A1 (en) 2018-05-09 2019-11-14 Children's Medical Center Corporation Mesenchymal stromal cell exosome -treated monocytes and uses thereof
CA3111661A1 (en) 2018-09-05 2020-03-12 Children's Medical Center Corporation Use of mesenchymal stromal cell exosomes in antenatal therapy

Also Published As

Publication number Publication date
CN112334190A (zh) 2021-02-05
CN112334190B (zh) 2024-09-20
EP3810271A1 (en) 2021-04-28
US12521418B2 (en) 2026-01-13
JP2024138218A (ja) 2024-10-08
US20210137989A1 (en) 2021-05-13
JP2021523106A (ja) 2021-09-02
EP3810271A4 (en) 2022-01-26
WO2019217091A1 (en) 2019-11-14
JP7538044B2 (ja) 2024-08-21

Similar Documents

Publication Publication Date Title
US12521418B2 (en) Mesenchymal stromal cell exosomes and uses thereof
Chaubey et al. Early gestational mesenchymal stem cell secretome attenuates experimental bronchopulmonary dysplasia in part via exosome-associated factor TSG-6
US20200306319A1 (en) Methods for treating radiation or chemical injury
Tokalov et al. Age-related changes in the frequency of mesenchymal stem cells in the bone marrow of rats
EP2001998B1 (en) Methods and compositions for the repair and/or regeneration of damaged myocardium
JP7563976B2 (ja) 歯髄由来細胞の製造方法
US20250170183A1 (en) Method for enriching muse cells and obtaining exosomes, microvesicles or the secretome therefrom
US9926561B2 (en) Composition for regenerating normal tissue from fibrotic tissue
US20210213056A1 (en) Mesenchymal stromal cell exosome-treated monocytes and uses thereof
KR20200128501A (ko) 성체줄기세포 유래의 나노베시클 및 이의 표적 치료용 용도
Abedi et al. Robust conversion of marrow cells to skeletal muscle with formation of marrow-derived muscle cell colonies: a multifactorial process
EP4017512A1 (en) Compositions for monocyte and macrophage polarization and methods of use
JP2022517342A (ja) 幹細胞機能を向上させるための薬剤及び方法
WO2021153719A1 (ja) 歯髄由来細胞を含む医薬組成物
US12090166B2 (en) Pharmaceutical composition for preventing or treating dentin-dental pulp disease or periodontal disease, containing LPAR2 inhibitor
Class et al. Patent application title: MESENCHYMAL STROMAL CELL EXOSOMES AND USES THEREOF
Park et al. Co-transplantation of human mesenchymal stem cells promotes human CD34+ cells engraftment in a dose-dependent fashion in NOD/SCID mice
JP2023543149A (ja) 幹細胞機能を向上させるための組成物及び方法
KR20140132205A (ko) Amd3100을 포함하는 골질환 예방 또는 치료용 조성물
RU2795621C2 (ru) Способ получения клеток из зубной пульпы
KR101813079B1 (ko) 에키노크롬 a를 유효성분으로 함유하는 심근세포 분화유도용 조성물
Osman Kuersetin Ile ZenginleŞTirilmiŞ Kordon KaynaklI Mezenkimal KÖK HÜCre EksozomlarININ, LPS IndÜKlÜ HMC3 Mikroglia NÖRoinflamasyon Modelinde, Antienflamatuar Etkisinin Incelenmesi
JP2018074983A (ja) 未分化細胞が除去された分化誘導細胞集団の製造方法
EP1951214A2 (en) Modulation of osteoclast differentiation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220916

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250123

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250418

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250418

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250523

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250724

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250724